Abstract: The present invention relates to a compound of formula (I) wherein:—i is 0 or 1; j is 0 or 1; k is 0 or 1;—R1 and R2 are in particular H, (C1-C12)alkyl, or a group of formula C(O)R;—R is a, linear or branched, alkyl radical, comprising at least 19 carbon atoms;—R3 is H and k=0 when j=1; or, when j=0, R3 is —C(O)R or -L-C(O)R;—L, U and L? are linkers; wherein, when j=0, at least one of the groups R1; R2 and R3 comprises a radical R.

Abstract: Racemic or optically active D- or L-?-glycerophosphoryl choline solids are prepared from liquid type racemic or optically active D- or L-?-glycerophosphoryl choline using an organic solvent. The solids are produced at a high yield more easily through phase transformation than an existing method using a difference in solubility in a solvent.

Abstract: A phosphate ester composition comprising more than 50 mass % of a phosphate ester represented by Formula 1, wherein X, Y, and Z are independently selected from the group consisting of alkyl, heteroalkyl, heteroaryl or aryl, with at least one of X, Y and Z being aryl, represented by Formula 2, and wherein two or more of R3, R4 and R5 have from 1 to 10 carbon atoms, and the total number of carbon atoms in R3, R4 and R5 is from 3 to 30. The use of the phosphate ester composition as a flame retardant, a lubricant, an anti-wear additive, a hydraulic fluid, a self-extinguishing functional fluid, or an additive thereof.

Abstract: Provided herein is a use of a high-boiling solvent in a mixture comprising a (thio)phosphoric acid derivative and a process including the addition of a high-boiling solvent to a mixture comprising a (thio)phosphoric acid derivative to recover the (thio)phosphoric acid from the mixture by an evaporation process.

Abstract: Gold(I) complex with mixed ligands as an anticancer agent. The gold(I) ion is coordinated to a dithiocarbamate ligand and a phosphorus-containing ligand (e.g. phosphines). Also described are a pharmaceutical composition incorporating the gold(I) complex, a methods of synthesizing the gold(I) complex, and a method for treating cancer.

Abstract: Gold(I) complex with mixed ligands as an anticancer agent. The gold(I) ion is coordinated to a dithiocarbamate ligand and a phosphorus-containing ligand (e.g. phosphines). Also described are a pharmaceutical composition incorporating the gold(I) complex, a methods of synthesizing the gold(I) complex, and a method for treating cancer.

Abstract: The present invention relates to a process for phospholipidation of imidazoquinolines and oxoadenines. More particularly, the present invention relates to a high-yielding and scalable procedure for the phospholipidation of imidazoquinolines and oxoadenines which obviates the need to isolate unstable phosphoramidite intermediates. This process may be used for the phospholipidation of toll-like receptor 7 (TLR7)-active and toll-like receptor (TLR8)-active imidazoquinolines and oxoadenines.

Abstract: The invention relates to bismuth perfluoroalkylphosphinates as Lewis acid catalysts, the compounds, and processes for the preparation thereof. ArxBi[OP(O)(Rf)2]3-x??(Ia), Ar3Bi[OP(O)(Rf)2]2??(Ib).

Abstract: An organometallic compound represented by Formula 1: M(L11)n1(L12)n2??Formula 1 wherein, in Formula 1, M is a third row transition metal, L11 is a ligand represented by Formula 2, n1 is 1 or 2, and when n1 is two, two groups L11 are identical to or different from each other, L12 is an organic ligand, n2 is 0, 1, 2, or 3, and when n2 is two or more, two or more of groups L12 are identical to or different from each other: wherein, in Formula 2, groups and variables are the same as described in the specification.

Abstract: An organometallic compound represented by Formula 1: M(L1)n1(L2)n2??Formula 1 wherein M, L1, L2, n1, and n2 are the same as described in the specification.

Abstract: Disclosed are carbon monoxide releasing complexes comprising a transition metal, at least one carbon monoxide ligand, and a pH responsive ligand that modulates the release of carbon monoxide, compositions comprising such complexes, and methods of using such compounds for treating various diseases and conditions and preserving cells, tissue or organs for transplantation.

Abstract: The present invention relates to a method for efficiently producing a ruthenium complex (1A) by reacting a dinuclear ruthenium complex (2A) with a compound (3A) in the presence of a primary alcohol and a base. The ruthenium complex (1A) can also be efficiently produced by treating a dinuclear ruthenium complex (4A) with a primary alcohol and a base. (In the formulas, solid lines, triple lines, broken lines, C, H, N, OP, Ru, X, AH and R1 to R12 have the meanings defined in the specification.

Abstract: Platinum(II) complexes with various selones (L) having the general formula PtL2Cl2 are disclosed. The platinum(II) complexes of the invention inhibit growth of cancer cells in vitro and are useful for treatment of proliferative disorders such as cancers and/or tumors.

Abstract: The present teachings relate to compounds and compositions for treatment of cancers. In some embodiments, the composition comprises a platinum (IV) complex having at least one carboxylate or carbamate ligand.

Abstract: The present invention relates to a method for the preparation of a metal-organic framework structure compound, the metal-organic framework structure compound being prepared such as well as the use of the metal-organic framework structure compound being prepared such as adsorbent.

Abstract: Biomass feedstocks (e.g., plant biomass, animal biomass, and municipal waste biomass) are processed to produce useful products, such as fuels. For example, systems are described that can use feedstock materials, such as cellulosic and/or lignocellulosic materials and/or starchy materials, to produce a product or intermediate, e.g., energy, a food, a fuel, or a material.

Abstract: The present invention relates to a xylene-based amphiphilic compound, a method for preparing the same, and a method for extracting, solubilizing, stabilizing or crystallizing a membrane protein using the same. By using the xylene-based compound according to the present invention, a membrane protein may be stably stored in an aqueous solution for a long time, and may be applied in functional and structural analyses. The structural and functional analysis of the membrane protein is one of the fields of highest interest in biology and chemistry, and the xylene-based compound according to the present invention can be applied in research on protein structure that is closely related to development of a new drug.

Abstract: Provided are certain derivatives of amphotericin B (AmB) characterized by reduced toxicity and retained anti-fungal activity. Certain of the derivatives are C16 urea derivatives and C16 carbamate derivatives of AmB. Also provided are methods of making the AmB derivatives.

Abstract: Disclosed are derivatives of amphotericin B (AmB) characterized by improved therapeutic index compared to AmB. The AmB derivatives include C16 ureas, carbamates, and amides according to Formula (I); C3?-substituted C16 ureas, carbamates, and amides according to Formula (II); C16 acyls according to Formula (III); C2?epi-C16 ureas, carbamates, and amides according to Formula (IV); and C16 oxazolidinone derivatives according to Formula (V). Also disclosed are pharmaceutical compositions comprising the AmB derivatives, and therapeutic methods of using the AmB derivatives.

Abstract: Provided herein are compounds of Formula (I) and pharmaceuticals acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, and prodrugs thereof. Also provided are pharmaceutical compositions, kits, and methods involving the inventive compounds for the treatment of an infectious disease (e.g., bacterial infection (e.g., tuberculosis, methicillin-resistant Staphylococcus aureus).

Abstract: The present invention discloses compounds of formula (I): which exhibit antiviral properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of anti-HBV treatment. The invention also relates to methods of treating a HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: A process for preparing phosphoramidates of nucleosides where a desired enantiomer, having regard to the asymmetric chiral center of the phosphorus atom P, is provided in an enriched amount. The process comprises admixing a nucleoside with a phosphorochloridate in the presence of a catalyst comprising a metal salt selected from the group consisting of salts of Cu, Fe, La and Yb.

Abstract: Provided herein are methods and compositions for synthesizing 5?Capped RNAs wherein the initiating capped oligonucleotide primers have the general form m7Gppp[N2?Ome]n[N]m wherein m7G is N7-methylated guanosine or any guanosine analog, N is any natural, modified or unnatural nucleoside, “n” can be any integer from 0 to 4 and “m” can be an integer from 1 to 9.

Abstract: The present embodiments provide methods, compounds, and compositions for inhibiting KRAS expression, which can be useful for treating, preventing, or ameliorating a disease associated with KRAS.

Abstract: Compounds of formula (I) wherein Base1 and Base2 are defined as in claim 1 are modulators of STING.

Abstract: The present invention relates to compounds characterized by having a structure according to the following Formula I: or a pharmaceutically acceptable salt thereof. Compounds of the present invention are useful for the treatment or prevention of HIV.

Abstract: The present invention provides, in certain aspects, novel 7-dehydrocholesterol (7DHC) derivatives that are useful in treating or preventing cancer, as well as in treating or preventing uncontrolled angiogenesis, in a subject. In certain embodiments of the present invention, the subject is a human. In other aspects, the present invention provides a method of preparing compounds of the invention, or a salt or solvate thereof.

Abstract: The invention provides a one-step process for preparing a cell-binding agent cytotoxic agent conjugate comprising contacting a cell-binding agent with a cytotoxic agent to form a first mixture comprising the cell-binding agent and the cytotoxic agent and contacting the first mixture comprising the cell-binding agent and the cytotoxic agent with a bifunctional crosslinking reagent, which provides a linker, in a solution having a pH of about 4 to about 9 to provide a second mixture comprising the cell-binding agent cytotoxic agent conjugate, wherein the cell-binding agent is chemically coupled through the linker to the cytotoxic agent, free cytotoxic agent, and reaction by-products. The second mixture is then optionally subjected to purification to provide a purified cell-binding agent cytotoxic agent conjugate.

Abstract: Disclosed are purification systems and methods for providing purified preparations of antibodies from a fluid, particularly a biological fluid comprising or suspected to contain antibody (e.g., blood, serum, plasma, ascites fluid). Reusable and stable synthetic purification columns comprising membranes of a suitable separation matrix material, such as a nylon membrane or regenerated cellulose membrane, having conjugated thereto a small molecule capture ligand, such as a short peptide or protein capable of acting as a ligand for a particular antibody of interest, such as a peptide having a sequence with binding affinity for a nucleotide binding site (NBS) of a selected antibody of interest, are also provided. Methods of preparing the purification columns are also disclosed. Methods for preparing high yield and high purity therapeutic antibody preparations, such as anti-cancer therapeutics, from a biological fluid, are also presented.

Abstract: Sample plates and methods for exchanging buffer solutions are disclosed herein. The sample plates and methods may be used with automated buffer exchange systems where high pressures, for example, pressures of at least about 30 psig, are applied across a filtering membrane. Methods for manufacturing the sample plates are further disclosed.

Abstract: The present disclosure is directed to HER2-specific peptide reagents, methods for detecting pre-cancer (dysplasia), early cancer and/or cancer using the peptide reagents, and methods for targeting pre-cancerous (dysplastic) cells, and/or cancer cells using the peptide reagents.

Abstract: The invention provides a molecule that inhibits or prevents an interaction between a Src family kinase and an androgen or estradiol receptor, for use in preventing or treating a non-cancerous condition in which an activity of AR and/or ER is a contributory factor in a subject, or for use in preventing or treating a cancerous condition in which an activity of AR and/or ER is a contributory factor in a subject who wishes to preserve fertility, or for use in preventing or treating a gynaecological condition in which an activity of AR and/or ER is a contributory factor in a subject.

Abstract: The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The gastrointestinal disorder may be classified as either irritable bowel syndrome, constipation, or excessive acidity etc. The gastrointestinal disease may be classified as either inflammatory bowel disease or other GI condition, including Crohn's disease and ulcerative colitis, and cancer.

Abstract: The disclosed peptidomimetic macrocycles modulate the activity of BFL-1 or a BCL-2 family protein. BFL-1, an anti-apoptotic BCL-2 family member, blocks p53-mediated apoptosis and has oncogenic transforming activity. Peptidomimetic macrocycles, pharmaceutical compositions, and methods disclosed herein can be used for the treatment of disease in which BFL-1 or a BCL-2 family protein is over-expressed, such as cancer. In particular, BFL-1-modulating or a BCL-2 family protein-modulating peptidomimetic macrocycles disclosed herein can be applied in the setting of resistance to BCL-2 family inhibitors, which is often engendered by BFL-1 or BCL-2 family protein over-expression or hyper-activation.

Abstract: Cloned filovirus genomic cDNA and methods of using the cDNA are provided. Further provided are noninfectious lipid encapsulated filovirus-based particles.

Abstract: Transgenic strains of Neurospora crassa engineered to comprise a synthetic positive feedback loop for a transcriptional activator of cellulase expression such that cellulase production is amplified are disclosed, along with compositions thereof. The transgenic strains are particularly useful in methods for generating purified cellulases, fermentable sugars, and cellulosic ethanol for the efficient production of biofuel from cellulose-containing biomass and waste.

Abstract: A protein comprising a moiety of 100-160 amino acid residues having at least 70% identity with the N-terminal (NT) fragment of a spider silk protein, wherein the amino acid residue corresponding to position 40 in NT is selected from the group consisting of Lys, Arg and His; and wherein the amino acid residue corresponding to position 65 in NT is selected from the group consisting of Asp and Glu, is useful as a moiety in a fusion protein for enhancing the solubility of another moiety in the fusion protein, which is a desired protein or polypeptide.

Abstract: A system, including methods and compositions, for treatment of ischemia.

Abstract: The present invention provides silk fibroin micro-particles having a high crystallinity index (1.3-1.5) and low sphericity index (?0.01) and a process for the preparation thereof. The high crystallinity index confers longer degradation periods to the instant silk fibroin micro-particles, therefore facilitating their use in biomedical applications.

Abstract: The present invention relates to novel chimeric molecules of ficolin-associated polypeptides, such as fusion polypeptides for the use in the treatment of conditions associated with inflammation, apoptosis, autoimmunity, coagulation, thrombotic or coagulopathic related diseases. The present invention further relates to nucleic acid molecules encoding such fusion polypeptides, vectors and host cells used in the production of the fusion polypeptides.

Abstract: A polynucleotide comprising a nucleotide sequence encoding the retinitis pigmentosa GTPase regulator ORF15 isoform (RPGRORF15), wherein the RPGRORF15-encoding nucleotide sequence has been codon optimised to increase fidelity of replication of the sequence.

Abstract: The present disclosure relates to compositions and methods for cancer therapy, including but not limited to, targeted inhibition of cancer markers. In particular, the present disclosure relates to recurrent gene fusions as clinical targets for cancer.

Abstract: The present invention provides a modified interleukin-7 and a use thereof. The modified IL-7 or an IL-7 fusion protein of the present invention comprising the same can be obtained in high yield, and biologically active in viral infection and cancer models. Therefore, they can be used for the prevention and treatment of various diseases.

Abstract: A compressible adjunct is used with a surgical instrument. The compressible adjunct includes a hollow fibrous construct and a core fibrous construct housed within the hollow fibrous construct, wherein the hollow fibrous construct comprises at least one biocompatible material that has experienced at least one transition from a more ordered phase to a less ordered phase in response to heating the hollow fibrous construct to a predetermined temperature.

Abstract: The present invention provides a marker for ADHD and applications thereof. The marker is ghrelin, and the marker can screen for potential ADHD patients by detecting the marker in peripheral blood or cerebrospinal fluid. Further, the present invention provides a new drug for the treatment of ADHD, providing the possibility and hope of new treatment for ADHD patients.

Abstract: The present invention relates to inhibin analogs, their method of production and their use in the treatment and prophylaxis of disease or conditions associated with reduced levels of inhibin and activin-mediated signaling.

Abstract: This document provides methods and materials related to insulin secreting polypeptides. For example, polypeptides having the ability to induce insulin secretion and methods and materials for using use such polypeptides to induce insulin secretion and to treat diabetes are provided.

Abstract: Disclosed herein are cells that are immune cells or precursor cells thereof, which cells recombinantly express a chimeric antigen receptor (CAR), and a dominant negative form of an inhibitor of a cell-mediated immune response of the immune cell, wherein the CAR binds to a cancer antigen. Also disclosed herein are T cells that recognize and are sensitized to a cancer antigen, which T cells recombinantly express a dominant negative form of an inhibitor of a T cell-mediated immune response. Additionally provided are methods of using such cells to treat cancer in a subject in need thereof.

Abstract: The present invention pertains to antigen recognizing constructs against tumor associated antigens (TAA), in particular against Preferentially Expressed Antigen of Melanoma (PRAME). The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the tumor expressed antigen of the invention. The TCR of the invention, and TAA binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of TAA expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.

Abstract: The present invention relates to a p75NTR neurotrophin binding protein (NBP)-Fc fusion protein comprising a p75NTR(NBP) portion and an immunoglobulin portion. In certain embodiments, the p75NTR(NBP)-Fc fusion protein is for use in the treatment of pain and/or a symptom of pain.